Resumen

LIZCANO, L  y  MAGALDI, L. Farmacovigilancia del Midazolam en Pacientes sometidos a Estudios Gastroscópicos. AVFT [online]. 2001, vol.20, n.2, pp.139-142. ISSN 0798-0264.

In a descriptive transversal study were included 160 patients admitted in gastroscopy studies at Centro Médico Docente La Trinidad. Midazolam (Doricum) was used as sedative at doses of 5 mg. Adverse Reaction (AR) were evaluated during and posteriori at the study using a Farmavigilance yellow card from the Centro de Vigilancia Farmacológica de Enfermería (CEVIFARE). During the procedure the most frequently AR were agitation 25% scream (12,5%), taquipnea (10%) and bradipnea (5%). After procedure were somnolence (100%), seasickness (45%) ataxia (40%), anterograd amnesia (35%) All AR observed were classified in type fouded that 100% were Type A. Durig the study AR were evaluated by severity founded 100% moderate and after 25% were light and 75% moderate. When AD were analized by their imputability during procedure 50% were posible and 50% probable, after procedure 100% were produced by midazolam. Nursing Farmacovigilance give very important information about drugs AR and in this study permitted avoid patients accident cause by ataxia and seasickness or cardiovascular changes induced by Midazolam in gastroscopy studies.

Palabras clave : Farmacovigilance; Adverse Reaction (AR); Midazolam; Gastroscopy.